



## **Cystic Fibrosis: Genetics, Pathophysiology and Novel Therapeutic Approaches**

Guest Editors:

**Prof. Dr. Massimo Conese**

Department of Clinical and  
Experimental Medicine,  
University of Foggia, 71122  
Foggia, Italy

**Dr. Onofrio Laselva**

Laboratory of Experimental and  
Regenerative Medicine,  
Department of Medical and  
Surgical Sciences, University of  
Foggia, 71122 Foggia, Italy

Deadline for manuscript  
submissions:

**closed (30 June 2022)**

### **Message from the Guest Editors**

Cystic fibrosis (CF) is a life-threatening autosomal recessive disorder due to mutations in the CF Transmembrane Conductance Regulator (*CFTR*) gene that cause morbidity and mortality mainly by inducing lung disease. This Special Issue is devoted to appraising the most recent developments in CF research and its clinical facets, focusing on the fields of genetics, theranostics, immunology, infections, inflammation, and novel therapeutic approaches. In the coronavirus 2019 (COVID-19) era, the natural history of CF pathophysiology is changing, thereby this Special Issue will be insightful in discussing how the present pandemic infection could determine other clinical features in CF patients. Finally, basic and applied research have sought and identified etiological treatments for CF, highlighted by the clinical use of modulators (potentiators, correctors) of the mutated CFTR protein. Novel genetic and stem cell-based treatments as potential therapeutic approaches to cure CF are at the forefront of CF research and will be also covered in this Special Issue.

